{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122300","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.899558+00:00","generated_at":"2026-05-30T04:33:41.871664+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"REGENXBIO Q3 net loss $59.6M; cash $278.6M; RGX-202 pivotal trial initiation expected this month","bullets":["Net loss of $59.6M ($1.17 EPS) vs $61.9M ($1.41 EPS) in Q3 2023.","Revenue $24.2M, down from $28.9M, driven by lower Zolgensma royalties ($23.9M vs $28.4M).","Cash, cash equivalents and marketable securities $278.6M as of Sep 30, 2024.","RGX-202 pivotal trial initiation and first functional data expected November 2024.","BLA submission for RGX-121 (MPS II) initiated, expected completion Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122300","json":"https://secwatch.observer/filing/0000950170-24-122300.json","markdown":"https://secwatch.observer/filing/0000950170-24-122300.md","text":"https://secwatch.observer/filing/0000950170-24-122300.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/0000950170-24-122300-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017024122300/rgnx-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:33:41.871664+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}